Literature DB >> 1891080

HTLV-I-associated myelopathy/tropical spastic paraparesis in the United States.

R S Janssen1, J E Kaplan, R F Khabbaz, R Hammond, R Lechtenberg, M Lairmore, M A Chiasson, A Punsalang, B Roberts, R R McKendall.   

Abstract

HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is endemic in the Caribbean basin and Japan. Because of the close proximity of the United States to the Caribbean and the presence of HTLV-I-seropositive persons in the United States, we sought reports of patients who were HTLV-I seropositive and had a slowly progressive myelopathy. Over a 2-year period, there were 25 patients reported, 19 of whom were black and 12 of whom had been born in the United States. All patients except two had become symptomatic while living in the United States. Six patients had no apparent risk factor for acquiring HTLV-I. These data demonstrate that HAM/TSP is occurring in the United States and that the diagnosis of HAM/TSP should be considered in patients with a slowly progressive myelopathy regardless of risk factors for acquiring HTLV-I.

Entities:  

Mesh:

Year:  1991        PMID: 1891080     DOI: 10.1212/wnl.41.9.1355

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.

Authors:  Michael S Mitchell; Ellen T Bodine; Shawn Hill; Gerald Princler; Patricia Lloyd; Hiroaki Mitsuya; Masao Matsuoka; David Derse
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

2.  Differential diagnosis of HTLV-I-associated myelopathy and multiple sclerosis in Iranian patients.

Authors:  B Kitze; R W Turner; M Burchhardt; S Poser; G Hunsmann; T Weber
Journal:  Clin Investig       Date:  1992-11

3.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.